Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10% following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui, which is expected to enhance domestic production capabilities in the medical isotope sector [1] Group 1: Company Developments - The launch event on October 31 marked the initiation of a project that will produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually [1] - The high-abundance 13CO gas is a critical raw material used in urea breath tests for detecting Helicobacter pylori infections [1] - The project signifies a shift from reliance on imported 13CO gas for urea breath diagnostic materials, establishing a fully autonomous supply chain in the medical stable isotope carbon field in China [1] Group 2: Industry Impact - The establishment of this production line is expected to provide a solid foundation for creating a safe and reliable high-end medical isotope supply chain in China [1] - The project represents a comprehensive control over the entire industry chain from key raw materials to end products in the medical stable isotope sector [1]

Core Viewpoint - The launch of the stable isotope base phase II project by China Tongfu marks a significant advancement in the domestic production of high-abundance 13CO gas and 13C urea raw materials, reducing reliance on imports and establishing a comprehensive domestic supply chain for medical stable isotopes [1] Group 1 - The project, initiated on October 31, aims to produce 2000 kilograms of high-abundance 13CO gas and 4000 kilograms of 13C urea raw materials annually [1] - High-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] - The launch signifies China's achievement in establishing a fully autonomous and controllable supply chain in the medical stable isotope carbon sector, from key raw materials to end products [1]